June 19, 2018
Once-daily oral baricitinib 4 mg was associated with significant clinical improvements compared with placebo in patients with systemic lupus erythematosus (SLE) receiving standard background therapy, according to data presented at the European League Against Rheumatism (EULAR) Congress held in Amsterdam, June 13 to 16, 2018….
A significantly greater percentage of patients in the baricitinib 4 mg group achieved resolution of SLEDAI-2K arthritis or rash (67% vs 53%; P <.05) and SRI-4 response (64% vs 48%; P <.05) at 24 weeks compared with placebo. In addition, the percentage of patients achieving flare reduction, Lupus Low Disease Activity State, and tender joint count change from baseline were also more improved in the baricitinib 4 mg group compared with placebo.
Source: Rheumatology Advisor
